Creo Medical’s Innovative Lung Cancer Study: A Potential Game-Changer

Creo Medical ((GB:CREO)) announced an update on their ongoing clinical study.

Creo Medical is currently conducting a study titled ‘Assessment of the Safety and Performance of the AB1 Electrosurgical System for Bronchoscopic Microwave Ablation of Lung Tissue in Surgical Candidates.’ The study aims to evaluate the safety and effectiveness of the MicroBlate™ Flex AB1 instrument in patients with confirmed malignant lung nodules who are eligible for surgical resection. This research is significant as it could offer a less invasive treatment option for lung cancer patients.

The intervention being tested is a device known as the MicroBlate™ Flex AB1, which is designed for bronchoscopic microwave ablation. This device aims to treat malignant lung nodules before surgical resection, potentially improving patient outcomes.

The study is observational in nature, following a cohort model with a prospective time perspective. It focuses on collecting data from patients undergoing the microwave ablation procedure to assess its safety and performance.

The study began on November 13, 2024, with the latest update submitted on June 23, 2025. These dates are crucial as they mark the progression and current status of the study, which is still recruiting participants.

This study update could positively influence Creo Medical’s stock performance by showcasing the company’s commitment to innovative cancer treatments. It may also impact investor sentiment positively, especially if the results demonstrate significant benefits over existing treatments. In the broader industry context, this could position Creo Medical as a leader in minimally invasive cancer therapies.

The study is ongoing, with further details available on the ClinicalTrials portal.